Cited by 74Menopause: Health Impacts and TreatmentsEstrogen and related hormone effectsHormonal and reproductive studies

The Estrogen Replacement and Atherosclerosis (ERA) Study

Herrington, David M., Reboussin, David M., Klein, Karen Potvin, Sharp, Penny C., Shumaker, Sally A., Snyder, Thomas E., Geisinger, Kim R.·2000·Controlled Clinical Trials

Abstract

The Estrogen Replacement and Atherosclerosis (ERA) trial is a three-arm, randomized, placebo-controlled, double-blind trial to evaluate the effects of estrogen replacement therapy (0.625 mg/day oral conjugated estrogen) with or without continuous low-dose progestin (2.5 mg oral medroxyprogesterone acetate/day) versus placebo on progression of atherosclerosis. A total of 309 postmenopausal women at five sites underwent baseline coronary angiography and were randomized. Participants will have repeat coronary angiography after an average of 3.25 years of treatment. The primary outcome of interest will be change in minimum diameter of the major epicardial segments, as assessed by quantitative coronary angiography. The primary aim is to test the hypothesis that either form of hormone therapy will slow the progression or induce regression of coronary atherosclerosis compared to placebo. The secondary aims are to assess the effects of the two treatments versus placebo on endothelial function (measured using flow-mediated vasodilator responses), on several presumed mediators of estrogen's effect on atherosclerosis (i.e., plasma lipids and lipoproteins, blood pressure, glucose metabolism, hemostatic factors, and antioxidant activity), on other factors that influence the development of coronary heart disease (i.e., diet, smoking status, exercise, weight, and health-related quality of life issues), and on clinical cardiovascular events. The ERA trial is the first angiographic endpoint clinical trial to examine the effects of postmenopausal hormone replacement on coronary atherosclerosis in women. It will provide an unparalleled opportunity to determine if either regimen of hormone therapy is effective in slowing the progress of angiographically defined coronary atherosclerosis. This study will complement other estrogen replacement trials, such as the PEPI, HERS, and Women's Health Initiative studies, to provide a more comprehensive examination of the effects of estrogen replacement on cardiovascular risk factors, anatomic and functional manifestations of atherosclerosis, and risk for coronary heart disease in postmenopausal women. Control Clin Trials 2000;21:257-285

Integrity signals

Registry

Crossref · 10.1016/s0197-2456(00)00054-4

Cites

70 of 70 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Herrington, D. M., Reboussin, D. M., Klein, K. P., Sharp, P. C., Shumaker, S. A., Snyder, T. E., & Geisinger, K. R.
Affiliations
Wake Forest University Health Sciences (US)
Corresponding author
Herrington, David M.
Venue
Controlled Clinical Trials
Publisher
Elsevier BV
Published
2000-06
Volume
21
Issue
3
Pages
257-285
ISSN
0197-2456 (ISSN-L)
OpenAlex
W54563526
Cited by
74
References
70
Citations by year
2026: 1 · 2025: 1 · 2023: 1 · 2021: 1 · 2017: 4 · 2015: 1 · 2014: 1 · 2013: 4 · 2012: 2
FWCI
5.58
Type
journal article
Language
en
Open access
closed
Locations
  • Controlled Clinical Trials (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • National Heart, Lung, and Blood Institute (U01 HL45888)
  • National Center for Research Resources (M01RR-07122, M01RR007122)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Menopause: Health Impacts and Treatments
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Estrogen and related hormone effects
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal and reproductive studies
Keywords
estrogen replacement therapy, conjugated estrogens, medroxyprogesterone acetate, postmenopausal women, coronary artery disease, atherosclerosis regression, coronary angiography, quantitative coronary angiography, endothelial function, flow-mediated dilation, cardiovascular risk factors, plasma lipids, blood pressure, glucose metabolism, hemostasis, antioxidant activity, health-related quality of life
MeSH terms
Aged, Arteriosclerosis, Double-Blind Method, Drug Therapy, Combination, Estrogens, Female, Follow-Up Studies, Humans, Lipids, Medroxyprogesterone, Middle Aged, Quality of Life, Research Design, Smoking, Exercise, Estrogen Replacement Therapy, Treatment Outcome, Coronary Angiography, Postmenopause, Progesterone Congeners

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review